1
NR 566 FINAL EXAM ADVANCED PHARMACOLOGY
2026/2027 | Newest Actual Exam Complete 160 Questions |
Detailed Verified Answers | A+ Graded | Pass Guaranteed
Section 1: Complex Cardiovascular Pharmacology - Advanced HF, Arrhythmias,
Anticoagulation (Questions 1-25)
Q1. A 68-year-old male with HFrEF (LVEF 30%, NYHA Class III) is currently on lisinopril
20 mg daily, metoprolol succinate 100 mg daily, and furosemide 40 mg daily. His BP is
118/72 mmHg and serum potassium is 4.2 mEq/L. The NP plans to initiate
sacubitril/valsartan (Entresto). Which action is REQUIRED before starting this
medication?
A. Discontinue metoprolol succinate 48 hours prior
B. Discontinue lisinopril and allow a 36-hour washout period [CORRECT]
C. Obtain a baseline troponin level
D. Start spironolactone simultaneously
Rationale: Sacubitril/valsartan must not be initiated within 36 hours of an ACE
inhibitor due to risk of angioedema. Metoprolol does not require discontinuation (A);
troponin (C) is not required; spironolactone (D) may be added later but is not required
before ARNI initiation.
Correct Answer: B
Q2. A patient on sacubitril/valsartan 49/51 mg BID is being titrated. Which target dose
represents the maximum recommended maintenance dose?
A. 24/26 mg BID
B. 49/51 mg BID
C. 97/103 mg BID [CORRECT]
D. 150/150 mg BID
Rationale: The target maintenance dose of sacubitril/valsartan is 97/103 mg BID,
titrated every 2-4 weeks from the starting dose of 49/51 mg BID. 24/26 mg is the
starting dose for patients not previously on ACEI/ARB.
Correct Answer: C
,2
Q3. A 72-year-old with HFrEF is started on vericiguat (Verquvo). The NP counsels the
patient to avoid which medication class due to risk of hypotension?
A. Beta-blockers
B. PDE5 inhibitors (sildenafil, tadalafil) [CORRECT]
C. Statins
D. Calcium channel blockers
Rationale: Vericiguat is an sGC stimulator; concurrent use with PDE5 inhibitors is
contraindicated due to synergistic hypotensive effects. Beta-blockers (A) and statins (C)
are not contraindicated; CCBs (D) are used cautiously.
Correct Answer: B
Q4. The VICTORIA trial established the efficacy of vericiguat in which patient
population?
A. Stable HFrEF on optimal GDMT
B. Worsening HFrEF with recent hospitalization or IV diuretic use [CORRECT]
C. HFpEF with preserved ejection fraction
D. Acute decompensated HF requiring inotropes
Rationale: VICTORIA evaluated vericiguat in patients with worsening HFrEF (recent HF
hospitalization or need for IV diuretics). It is not indicated for stable HF (A), HFpEF (C),
or acute decompensated HF requiring inotropes (D).
Correct Answer: B
Q5. A 65-year-old with HFrEF (LVEF 25%, sinus rhythm) remains symptomatic despite
lisinopril 40 mg, carvedilol 25 mg BID, and spironolactone 25 mg daily. Heart rate is 88
bpm. Which medication is MOST appropriate to add?
A. Digoxin
B. Ivabradine [CORRECT]
C. Amiodarone
D. Diltiazem
Rationale: Ivabradine is indicated for HFrEF with sinus rhythm and HR ≥70 bpm on
maximally tolerated beta-blocker. Digoxin (A) is second-line; amiodarone (C) is for
arrhythmias; diltiazem (D) is contraindicated in HFrEF.
Correct Answer: B
Q6. Ivabradine exerts its therapeutic effect by:
,3
A. Blocking beta-1 adrenergic receptors
B. Inhibiting the funny current (If) in the sinoatrial node [CORRECT]
C. Blocking L-type calcium channels
D. Inhibiting sodium-potassium ATPase
Rationale: Ivabradine selectively inhibits the hyperpolarization-activated cyclic
nucleotide-gated (HCN) channel (funny current, If) in SA node cells, reducing heart rate
without affecting contractility. Beta-blockade (A), calcium channel blockade (C), and
Na+/K+-ATPase inhibition (D) describe other drug classes.
Correct Answer: B
Q7. Which condition is an ABSOLUTE contraindication to ivabradine use?
A. Hypertension
B. Acute decompensated heart failure
C. Atrial fibrillation [CORRECT]
D. Type 2 diabetes mellitus
Rationale: Ivabradine is contraindicated in atrial fibrillation because it is ineffective for
rate control in AFib and may increase AFib risk. It is not contraindicated in
hypertension (A), acute HF (B is a precaution), or diabetes (D).
Correct Answer: C
Q8. A patient on digoxin 0.25 mg daily presents with nausea, vomiting, and reports
seeing "yellow-green halos around lights." ECG shows frequent PVCs. Serum digoxin
level is 3.2 ng/mL. Which is the MOST appropriate antidote?
A. Naloxone
B. Digoxin-specific antibody fragments (DigiFab) [CORRECT]
C. Flumazenil
D. Protamine sulfate
Rationale: DigiFab (digoxin immune Fab) is the specific antidote for life-threatening
digoxin toxicity. Naloxone (A) is for opioid overdose; flumazenil (C) reverses
benzodiazepines; protamine (D) reverses heparin.
Correct Answer: B
Q9. Which electrolyte abnormality MOST increases the risk of digoxin toxicity?
A. Hyperkalemia
B. Hypokalemia [CORRECT]
, 4
C. Hypernatremia
D. Hypercalcemia
Rationale: Hypokalemia increases digoxin binding to Na+/K+-ATPase, potentiating
toxicity. Hypokalemia is more dangerous than hyperkalemia (A) in this context; sodium
(C) and calcium (D) are less directly involved.
Correct Answer: B
Q10. A patient on amiodarone is started on digoxin. The NP should anticipate:
A. Decreased digoxin levels requiring dose increase
B. Increased digoxin levels requiring dose reduction [CORRECT]
C. No interaction between these medications
D. Increased risk of hyperkalemia
Rationale: Amiodarone inhibits P-glycoprotein, increasing digoxin levels by
approximately 70-100%. Digoxin dose should be reduced by 50% when starting
amiodarone.
Correct Answer: B
Q11. Which antiarrhythmic drug is classified as Vaughan-Williams Class IA?
A. Lidocaine
B. Procainamide [CORRECT]
C. Amiodarone
D. Verapamil
Rationale: Procainamide is Class IA (moderate Na+ channel blockade, prolongs
repolarization). Lidocaine (A) is IB; amiodarone (C) is III; verapamil (D) is IV.
Correct Answer: B
Q12. Flecainide is classified as Vaughan-Williams Class:
A. IA
B. IB
C. IC [CORRECT]
D. III
Rationale: Flecainide is Class IC (potent Na+ channel blockade, minimal effect on
repolarization). It is contraindicated in structural heart disease due to increased
NR 566 FINAL EXAM ADVANCED PHARMACOLOGY
2026/2027 | Newest Actual Exam Complete 160 Questions |
Detailed Verified Answers | A+ Graded | Pass Guaranteed
Section 1: Complex Cardiovascular Pharmacology - Advanced HF, Arrhythmias,
Anticoagulation (Questions 1-25)
Q1. A 68-year-old male with HFrEF (LVEF 30%, NYHA Class III) is currently on lisinopril
20 mg daily, metoprolol succinate 100 mg daily, and furosemide 40 mg daily. His BP is
118/72 mmHg and serum potassium is 4.2 mEq/L. The NP plans to initiate
sacubitril/valsartan (Entresto). Which action is REQUIRED before starting this
medication?
A. Discontinue metoprolol succinate 48 hours prior
B. Discontinue lisinopril and allow a 36-hour washout period [CORRECT]
C. Obtain a baseline troponin level
D. Start spironolactone simultaneously
Rationale: Sacubitril/valsartan must not be initiated within 36 hours of an ACE
inhibitor due to risk of angioedema. Metoprolol does not require discontinuation (A);
troponin (C) is not required; spironolactone (D) may be added later but is not required
before ARNI initiation.
Correct Answer: B
Q2. A patient on sacubitril/valsartan 49/51 mg BID is being titrated. Which target dose
represents the maximum recommended maintenance dose?
A. 24/26 mg BID
B. 49/51 mg BID
C. 97/103 mg BID [CORRECT]
D. 150/150 mg BID
Rationale: The target maintenance dose of sacubitril/valsartan is 97/103 mg BID,
titrated every 2-4 weeks from the starting dose of 49/51 mg BID. 24/26 mg is the
starting dose for patients not previously on ACEI/ARB.
Correct Answer: C
,2
Q3. A 72-year-old with HFrEF is started on vericiguat (Verquvo). The NP counsels the
patient to avoid which medication class due to risk of hypotension?
A. Beta-blockers
B. PDE5 inhibitors (sildenafil, tadalafil) [CORRECT]
C. Statins
D. Calcium channel blockers
Rationale: Vericiguat is an sGC stimulator; concurrent use with PDE5 inhibitors is
contraindicated due to synergistic hypotensive effects. Beta-blockers (A) and statins (C)
are not contraindicated; CCBs (D) are used cautiously.
Correct Answer: B
Q4. The VICTORIA trial established the efficacy of vericiguat in which patient
population?
A. Stable HFrEF on optimal GDMT
B. Worsening HFrEF with recent hospitalization or IV diuretic use [CORRECT]
C. HFpEF with preserved ejection fraction
D. Acute decompensated HF requiring inotropes
Rationale: VICTORIA evaluated vericiguat in patients with worsening HFrEF (recent HF
hospitalization or need for IV diuretics). It is not indicated for stable HF (A), HFpEF (C),
or acute decompensated HF requiring inotropes (D).
Correct Answer: B
Q5. A 65-year-old with HFrEF (LVEF 25%, sinus rhythm) remains symptomatic despite
lisinopril 40 mg, carvedilol 25 mg BID, and spironolactone 25 mg daily. Heart rate is 88
bpm. Which medication is MOST appropriate to add?
A. Digoxin
B. Ivabradine [CORRECT]
C. Amiodarone
D. Diltiazem
Rationale: Ivabradine is indicated for HFrEF with sinus rhythm and HR ≥70 bpm on
maximally tolerated beta-blocker. Digoxin (A) is second-line; amiodarone (C) is for
arrhythmias; diltiazem (D) is contraindicated in HFrEF.
Correct Answer: B
Q6. Ivabradine exerts its therapeutic effect by:
,3
A. Blocking beta-1 adrenergic receptors
B. Inhibiting the funny current (If) in the sinoatrial node [CORRECT]
C. Blocking L-type calcium channels
D. Inhibiting sodium-potassium ATPase
Rationale: Ivabradine selectively inhibits the hyperpolarization-activated cyclic
nucleotide-gated (HCN) channel (funny current, If) in SA node cells, reducing heart rate
without affecting contractility. Beta-blockade (A), calcium channel blockade (C), and
Na+/K+-ATPase inhibition (D) describe other drug classes.
Correct Answer: B
Q7. Which condition is an ABSOLUTE contraindication to ivabradine use?
A. Hypertension
B. Acute decompensated heart failure
C. Atrial fibrillation [CORRECT]
D. Type 2 diabetes mellitus
Rationale: Ivabradine is contraindicated in atrial fibrillation because it is ineffective for
rate control in AFib and may increase AFib risk. It is not contraindicated in
hypertension (A), acute HF (B is a precaution), or diabetes (D).
Correct Answer: C
Q8. A patient on digoxin 0.25 mg daily presents with nausea, vomiting, and reports
seeing "yellow-green halos around lights." ECG shows frequent PVCs. Serum digoxin
level is 3.2 ng/mL. Which is the MOST appropriate antidote?
A. Naloxone
B. Digoxin-specific antibody fragments (DigiFab) [CORRECT]
C. Flumazenil
D. Protamine sulfate
Rationale: DigiFab (digoxin immune Fab) is the specific antidote for life-threatening
digoxin toxicity. Naloxone (A) is for opioid overdose; flumazenil (C) reverses
benzodiazepines; protamine (D) reverses heparin.
Correct Answer: B
Q9. Which electrolyte abnormality MOST increases the risk of digoxin toxicity?
A. Hyperkalemia
B. Hypokalemia [CORRECT]
, 4
C. Hypernatremia
D. Hypercalcemia
Rationale: Hypokalemia increases digoxin binding to Na+/K+-ATPase, potentiating
toxicity. Hypokalemia is more dangerous than hyperkalemia (A) in this context; sodium
(C) and calcium (D) are less directly involved.
Correct Answer: B
Q10. A patient on amiodarone is started on digoxin. The NP should anticipate:
A. Decreased digoxin levels requiring dose increase
B. Increased digoxin levels requiring dose reduction [CORRECT]
C. No interaction between these medications
D. Increased risk of hyperkalemia
Rationale: Amiodarone inhibits P-glycoprotein, increasing digoxin levels by
approximately 70-100%. Digoxin dose should be reduced by 50% when starting
amiodarone.
Correct Answer: B
Q11. Which antiarrhythmic drug is classified as Vaughan-Williams Class IA?
A. Lidocaine
B. Procainamide [CORRECT]
C. Amiodarone
D. Verapamil
Rationale: Procainamide is Class IA (moderate Na+ channel blockade, prolongs
repolarization). Lidocaine (A) is IB; amiodarone (C) is III; verapamil (D) is IV.
Correct Answer: B
Q12. Flecainide is classified as Vaughan-Williams Class:
A. IA
B. IB
C. IC [CORRECT]
D. III
Rationale: Flecainide is Class IC (potent Na+ channel blockade, minimal effect on
repolarization). It is contraindicated in structural heart disease due to increased
